Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 Sep 1, 2019 Summary ToggleNovartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint Jul 1, 2019 Summary ToggleNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies Jul 1, 2019 Summary ToggleNovartis data underpin long-term efficacy of Aimovig® where other treatments have failed Jun 3, 2019 Summary ToggleXolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies Jun 1, 2019 Summary ToggleNovartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial May 24, 2019 Summary ToggleFDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer May 8, 2019 Summary ToggleNovartis data at AAN show Mayzent’s® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS May 2, 2019 Summary ToggleNovartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN Mar 26, 2019 Summary ToggleNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease Jan 29, 2019 Summary ToggleNovartis delivered accretive growth, focused the company and built leading advanced therapy platforms in 2018 Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
